Caflanone is a small molecule belonging to the flavonoid class of polyphenols. In preclinical studies, Caflanone inhibited the hCov-OC43 human Coronavirus with an EC50 of 0.42 µM. Some analogs of Caflanone inhibited OC43 with comparable EC50s. The human coronavirus hCov-OC43 belong to clade b of the genus Betacoronavirus same as SARS-COV-2
Recent mapping of the genome of SARS-COV-2 has revealed more than 20 proteins required for the entry and replication of SARS-COV-2 in humans. Two of the proteases (PLpro & 3CLpro) are vital to the virus replication with 3CLpro considered a viable therapeutic antiviral target. Computer aided drug design studies have shown strong binding affinity of Caflanone to the 3CLpro protease.
Glide score: -7.592
Docked with 3CLpro
Making 4 major
Interactions with protein
Caflanone has also shown inhibitory activity against other viral and host factors required in the viral life cycle.
A majority of IND-enabling safety studies for Caflanone have been completed. In addition, Caflanone passed early screening on the SafetyScreen44™ assay which is used by big pharma to assess and drop from further development drugs with safety liabilities.
The growing novel coronavirus, SARS-CoV-2, pandemic has resulted in over 4.6 million infections and 300,000 deaths as of May 20, 2020 according to statistics from the World Health Organization. Identification of effective antiviral agents to combat the SARS-CoV-2 is urgently needed. SARS- CoV-2 binds to their target cells through angiotensin-converting enzyme 2 (ACE2), which is expressed by epithelial cells of the lung, intestine, kidney, and blood vessels. Our research has identified a potent flavonoid Caflanone, with proven antiviral efficacy and potential to serve as an effective treatment and preventative prophylactic.
Vilotos aims to find a cure for novel coronavirus utilizing patent filed technology.